Aptevo Therapeutics Plunges 10.14% on $8M Offering

On June 20, 2025, Aptevo Therapeutics experienced a significant drop of 10.14% in pre-market trading, reflecting investor sentiment and market dynamics.

Aptevo Therapeutics recently announced an $8 million offering priced at-the-market under Nasdaq rules, which is expected to close on or around June 20, 2025. This offering includes 2.47 million shares of common stock or pre-funded warrants and 12.33 million common stock purchase warrants at a combined price of $3.25 per share. The proceeds from this offering are expected to be approximately $8 million, before deducting placement agent fees and offering expenses.

In clinical trials, Aptevo's mipletamig has shown promising results, with 85% of evaluable frontline AML patients achieving remission. The drug has demonstrated a strong safety profile, with no dose-limiting toxicities observed. This positive clinical data has contributed to the growing evidence supporting mipletamig as a potential treatment option for AML patients.

Aptevo Therapeutics has also been actively participating in industry conferences, such as the BIO International Convention, to showcase its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies. These platforms are the foundation for the company's novel immune-oncology therapeutics, which are designed to target specific pathways in cancer cells.

Additionally, Aptevo Therapeutics has announced a 1-for-20 reverse stock split as part of its Nasdaq compliance plan. This move is aimed at meeting the minimum bid price requirement for continued listing on the Nasdaq Stock Market. The reverse stock split will reduce the number of outstanding shares, which could potentially impact the stock price and investor perception.